Close Menu

NEW YORK ─ Eurofins on Thursday said its third quarter revenues increased 17 percent year over year to €1.4 million ($1.7 million) compared to €1.2 million in Q3 2019.

Organic growth was 22.7 percent, the Luxembourg-based company said.

Eurofins core business, excluding any COVID-19 clinical testing and reagents revenues, returned to "small positive organic growth in Q3 2020," the firm said in a statement, adding many of its core businesses ─ including food, environment, and biopharma testing ─ achieved greater than 5 percent organic growth in Q3 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Science reports that Science Foundation Ireland is seeking annual budget increases.

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.